Autor: |
de Moor, J.S., Klein, W.M.P., Spees, L.P., Prabhu Das, I., Roberts, M.C., Freedman, A.N., Butler, E.N. |
Rok vydání: |
2021 |
DOI: |
10.17615/s8h4-fe56 |
Popis: |
Objective: Next generation sequencing (NGS) may aid in tumor classification and treatment. Barriers to shared decision-making may influence use of NGS. We examined, from oncologists’ perspectives, whether barriers to involving patients/families in decision-making were associated with NGS use. Methods: Using data from the first national survey of medical oncologists’ perspectives on precision medicine (N = 1281), we approached our analyses in two phases. Bivariate analyses initially evaluated associations between barriers to involving patients/families in deciding to use NGS and provider- and organizational-level characteristics. Modified Poisson regressions then examined associations between patient/family barriers and NGS use. Results: Approximately 59 % of oncologists reported at least one barrier to involving patients/families in decision-making regarding NGS use. Those reporting patient/family barriers tended to have fewer genomic resources at their practices, to be in rural or suburban areas, and to have a higher proportion of Medicaid patients. However, these barriers were not associated with NGS use. Conclusions: Oncologists encounter barriers to involving patients/families in NGS testing decisions. Organizational barriers may also potentially play a role in testing decisions. Practice implications: To foster patient-centered care, strategies to support patient involvement in genomic testing decisions are needed, particularly among practices in low-resource settings. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|